Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses – IVY Network, September 1, 2022-March 30, 2023

By sjmartinez • November 14, 2024

Lewis NM, Harker EJ, Leis A, Zhu Y, Talbot HK, Grijalva CG, Halasa N, Chappell JD, Johnson CA, Rice TW, Casey JD, Lauring AS, Gaglani M, Ghamande S, Columbus C, Steingrub JS, Shapiro NI, Duggal A, Felzer J, Prekker ME, Peltan ID, Brown SM, Hager DN, Gong MN, Mohamed A, Exline MC, Khan A, Wilson JG, Mosier J, Qadir N, Chang SY, Ginde AA, Mohr NM, Mallow C, Harris ES, Johnson NJ, Srinivasan V, Gibbs KW, Kwon JH, Vaughn IA, Ramesh M, Safdar B, DeCuir J, Surie D, Dawood FS, Ellington S, Self WH, Martin ET. Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023. Vaccine. 2024 Nov 7;43(Pt 2):126492. doi: 10.1016/j.vaccine.2024.126492. Epub ahead of print. PMID: 39515195.

Tags: bias, covid-19, Estimation, Influenza, Publications, Pulmonary, Critical Care & Sleep Medicine, RSV, vaccine effectiveness

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, Bixby D, Chai-Ho W, Stahl M, Yee KWL, Stevens D, Ito S, Reynolds[...]

Non-Rigid Motion-Compensated MR Multitasking for Free-Breathing Low-Dose Dynamic Contrast-Enhanced MRI in the Abdomen

Ma L, Wu C, Wang L, Lee HL, Chen J, Hu Z, Xie Y, Pandol SJ, Gaddam S, Li D, Christodoulou AG. Non-Rigid Motion-Compensated MR[...]

Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease

Nalluri K, Goodman EL, Pasupneti T, Nunez G, Wang EC. Multifactorial causes of severe persistent hypercalcemia in an immunosuppressed woman with chronic kidney disease. JCEM[...]